$SCSC

BAUR MICHAEL L sold $4.4M of SCSC

BAUR MICHAEL L (CEO, President, BOD Chair) sold 77,339 shares of SCANSOURCE, INC. (SCSC) at an average of $57.39 ($55.39–$58.14, $4.44M total) across 5 trades over 2026-09-10 to 2026-09-11.

Original reporting
SEC EDGAR · BAUR MICHAEL L
Published Sep 14, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SCSC
Bearish
medium confidence
Mentioned
$SCSC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SCSCBearishLow
01

Why it matters

The CEO's $4.4 M share sale reduces his ownership, which may be interpreted as reduced confidence, potentially prompting short interest.

02

Market read

Primary insider sale news; may influence short‑term price action for SCSC.

03

What to watch

No 10b5‑1 plan was used, suggesting the timing was discretionary.

Relevance 6/10Novelty 7/10Timing: filing date 2026‑09‑14

Background

Scansource Inc. (NASDAQ:SCSC) provides healthcare technology solutions. Insider transactions are disclosed via Form 4.

Company-level read

Ticker impact

$SCSCBearishMedium confidence
Context

CEO Michael Baur sold 77,339 shares for $4.44M, reducing his stake to 200,698 shares.

Expected impact

Possible short-term downside as market digests the sale.

Evidence & confidence

The sale size is material for a mid‑cap and the insider is the CEO, which often influences investor perception.

Market effects

Minimal; the sale does not affect the broader medical device sector.

None; the filing is U.S. specific.

Low; only relevant to Scansource investors.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Michael Baur

    CEO, President, and Board Chair of Scansource, Inc.

  • Scansource, Inc.

    Medical device and technology company listed on NASDAQ under ticker SCSC.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SCSCMedAI 8/10

ScanSource (SCSC) Bets $220M On A Bigger IT Footprint

ScanSource (SCSC) completed a $220.5M cash acquisition of MicroAge. SCSC's Q4 saw 17.3% sales growth and 43% EPS increase. MicroAge is expected to boost margins and free cash flow. SCSC used credit facilities for the deal, doubling its debt. Q4 gross margin slipped to 12.6%. Fiscal 2027 guidance excludes MicroAge. Hedge fund ownership rose, and the stock trades at a forward P/E of 11.95.

$SCSCMed

United Community execs, ScanSource acquisition and BBQ: In the Know

ScanSource Inc. (SCSC) agreed to acquire MicroAge for $220.5M in cash, aiming to expand its market reach and enhance growth. The deal is expected to close in September, subject to regulatory approval. MicroAge serves 2,400 clients and offers IT solutions and managed services. ScanSource plans to fund the acquisition through its existing credit facility.

$SCSCHighAI 8/10

ScanSource Completes $220.5 Million Acquisition Of MicroAge

ScanSource completed its $220.5 million all-cash acquisition of MicroAge, expanding its cybersecurity and managed IT services. The deal, funded through existing credit facilities, is expected to boost margins and free cash flow. MicroAge's services complement ScanSource's distribution platform, supporting partners in complex tech environments.

$SCSCHighAI 8/10

ScanSource (SCSC) Just Posted Record Earnings And A Big Acquisition

ScanSource (SCSC) reported Q4 results with net sales up 17.3% to $953.1M and non-GAAP EPS up 43.1% to $1.46. The company announced a $220.5M acquisition of MicroAge. Hardware demand drove growth, while Brazil saw a 21.6% sales decline. Free cash flow was $113.8M, and the company has $121M left for buybacks. Fiscal 2027 guidance assumes large tech deployments return.